{
    "organizations": [],
    "uuid": "3d6295e56e204cdc250459081d39c387e00a80aa",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-raqualia-pharma-says-license-agree/brief-raqualia-pharma-says-license-agreement-for-novel-p2x7-receptor-antagonist-idUSL3N1R82XS",
    "ord_in_thread": 0,
    "title": "BRIEF-RaQualia Pharma says license agreement for novel P2X7 receptor antagonist",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 26(Reuters) - RaQualia Pharma Inc\n* Says it and Asahi Kasei Pharma Corp have entered into a license agreement for a novel P2X7 receptor antagonist discovered through a research collaboration between the two companies\nSource text in Japanese: goo.gl/TJ8sZH\nFurther company coverage: (Beijing Headline News)\n ",
    "published": "2018-03-26T14:50:00.000+03:00",
    "crawled": "2018-03-27T11:39:08.013+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "raqualia",
        "pharma",
        "inc",
        "say",
        "asahi",
        "kasei",
        "pharma",
        "corp",
        "entered",
        "license",
        "agreement",
        "novel",
        "p2x7",
        "receptor",
        "antagonist",
        "discovered",
        "research",
        "collaboration",
        "two",
        "company",
        "source",
        "text",
        "japanese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news"
    ]
}